Yantai, creating a three -dimensional industrial ecology of biomedical medicine

Jiaodong Online August 18 (Reporter Jia Chuhang Intern Zhao Wenlong) From August 18th to 19th, 2022 International Conference on Pharmaceutical Innovation and Development will be held at the Baying Bay International Conference Center of Yantai. Sexual meeting. Behind is the strong biomedical industry in Yantai.

In recent years, Yantai has focused on the key advantageous industry of biomedicine, first tried the "chain long system" working mechanism, introduced a new round of industrial development support policies, established an industrial development support system, paid close attention to the key points of project breakthroughs, and created the integration of full -chain elements fusion The three -dimensional industrial ecology.

The policy escort industry is steadily moving forward

A group of hard -approved biomedical companies are becoming a dazzling "star" on the Yantai Biomedical Industry Chain: In 2021, Rongchang Biological Thai Sip and Vidici Anti -two new drugs were approved to be listed and entered the national medical insurance catalog The number of innovative drugs accounts for nearly half of the province, and the number of new drugs in the province accounts for 2/3 of the province; two innovative drugs for the use of Lipidone microbolis and Bevarzon single anti -anti -counterfeit are approved. The leather stickers are approved in the EU; the "Polying Elephant Disterrotic Portal Modification Relocrey Portable Protection Portable Technical System Establishment and Industrialization" project has won the second prize of the National Science and Technology Progress of 2020.

The bright performance of the enterprise is inseparable from the full escort of the policy. Yantai Research and issued the "Several Opinions on Promoting the High -quality Development of the Biomedical Industry in the City". Make up shortcomings, build ecology, and continue to promote the nine major projects of chain leading, innovation platforms, clinical collaboration, carrier construction, talent introduction, financial assistance, digital fusion, attracting capacity expansion, and technical tackling. Equipped and clustering color, build the city's "1+3+X" biomedical industrial park's characteristic development layout. Strong protection and activation, introduce the entire industrial chain of "R & D+Clinical+Manufacturing+Application", "Investment+Intellectual Property+Talent" multi -factor industry development support policies, support R & D innovation, results transformation, platform construction, park construction, talent talent Gathering and promoting the implementation of the implementation of policies and the facilitation of the process of redeeming the policy.

Professional carrier breeding core competitiveness

The gathering of high -end R & D platforms is the key to building an industrial ecology. Yantai has continuously made efforts in the introduction of institutions, universities, and talents to help enterprises build R & D platforms, and injecting continuous vitality into the innovation and development of the biomedical industry.

Give full play to the integration of production talents in the industrial talent alliance. It has matched more than 30 national talents and set up 1 academician workstation; played the role of high -end think tanks of the Innovation and Development Research Institute. , Top experts in the field of medical isotopes, 28 well -known experts including head investment institutions such as Yingke Capital, Defu Capital, CITIC Medical, Huagai Capital, and other head investment institutions; Supply, capital, talent and other resource line integration, 150 institutions and 50 high -end talents have settled in institutions.

Together with the Shanghai Academy of Drug Institute of the Chinese Academy of Sciences, the Chinese Academy of Sciences Bohai (Yantai) Drug Advanced Research Institute was jointly created. Products build an innovative research and development platform.

At present, there are 49 species of pharmaceutical device products in the city, including 25 medicine products that enter the listing application stage, and 24 medicine products that enter the clinical research stage. From this year, our city will be listed on 1-2 kinds of innovative drugs every year. Rongchang Biotica and other listed products have been continuously expanded to the clinic of adaptive diseases. Nearly 20 types of anti-tumors and cure slow diseases have become large varieties. Has a good market prospect.

Fully layout advantage areas

The vigorous development of Yantai biomedical industry is also due to the precise positioning and comprehensive layout of the advantage areas.

Taking Dongcheng Pharmaceutical as the core, layout medical isotopic drugs and application technology industry chains. Accelerate the construction of an international medical isotope innovation application base. The first phase of the project will be completed by the end of the year. Ten upstream and downstream affiliated companies in Dongcheng Pharmaceuticals are gathered, covering R & D, production, and CRO services. More than 10 new drug projects are included in the pipeline.

With green leaf pharmaceutical as the core, the VLP innovation vaccine industry chain is deployed. Focusing on the three major R & D platforms of new preparations, new therapy entities/new molecular entities, and biological antibodies, it has continuously improved the value conversion of innovation capabilities and accelerating the value of innovation results. The Group's current research projects are in the listed review stage, and dozens of projects are in different clinical research stages. They have officially entered the harvest period of self -developed products and injected new impetus into the future growth of the enterprise.

With Rongchang Bio as the core, the targeted biological innovation pharmaceutical industry chain is deployed by the Rongchang Bio. Accelerate the construction of the industrialization project of Rongchang Biopharmaceuticals. It is expected to complete the main construction of the subject within the year and will be completed next year. After all, after the overall full load is put into production, the annual output value will be 25 billion yuan.

- END -